E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Pancreatic ductal adenocarcinoma |
Adenocarcinoma ductal pancreático |
|
E.1.1.1 | Medical condition in easily understood language |
Pancreatic Cancer​ |
Cáncer pancreático |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10033599 |
E.1.2 | Term | Pancreatic adenocarcinoma metastatic |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
- To assess safety and tolerability of AZD0171 in combination with durvalumab and chemotherapy in participants with 1L mPDAC - To determine the preliminary OS of AZD0171 in combination with durvalumab and chemotherapy in participants with 1L mPDAC |
-Evaluar la seguridad y la tolerabilidad de AZD0171 en combinación con durvalumab y quimioterapia en el tratamiento de primera línea (1L) de participantes con PDAC metastásico (mPDAC) -Determinar de manera preliminar la OS con AZD0171 en combinación con durvalumab y quimioterapia en el tratamiento de 1L de participantes con mPDAC |
|
E.2.2 | Secondary objectives of the trial |
- To further characterise the preliminary (i) antitumour activity and (ii) survival activity of AZD0171 in combination with durvalumab and chemotherapy in participants with 1L mPDAC - To assess the preliminary antitumour activity of AZD0171 in combination with durvalumab and chemotherapy in participants with 1L mPDAC via circulating biomarkers - To assess immunogenicity of AZD0171 and/or durvalumab - To determine the PK profile of AZD0171, durvalumab and chemotherapy in participants with 1L mPDAC including LIF bound to AZD0171 (total LIF) - To assess changes in CD8+ T cell tumour infiltration associated with AZD0171 treatment in combination with durvalumab and chemotherapy in participants with 1L mPDAC For additional information please refer to section 3 of the protocol. |
-Caracterizar ampliamente de manera preliminar (i) la actividad antitumoral, y (ii) la actividad en cuanto a la supervivencia de AZD0171 en combinación con durvalumab y quimioterapia en el tratamiento de 1L de participantes con mPDAC -Evaluar de manera preliminar la actividad antitumoral de AZD0171 en combinación con durvalumab y quimioterapia en el tratamiento de 1L en participantes con mPDAC a través de los biomarcadores en la circulación -Evaluar la inmunogenia de AZD0171 y/o durvalumab -Determinar el perfil farmacocinético (pharmacokinetic, PK) de AZD0171, durvalumab y quimioterapia (gemcitabina y nab-paclitaxel) en el tratamiento de 1L de participantes con mPDAC, incluido el LIF unido a AZD0171 LIF Total) -Evaluar los cambios en las células T CD8+ infiltrantes del tumor como resultado del tratamiento de 1L con AZD0171 en combinación con durvalumab y quimioterapia en participantes con mPDAC Para los objetivos y criterios de valoración exploratorios, véase la Sección 3 del CSP |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Eastern Cooperative Oncology Group performance status of 0 or 1 at screening/enrolment • Must have a Gustave Roussy Immune Score of 0 or 1 • Participants diagnosed with histologically confirmed pancreatic adenocarcinoma • Participants must have at least 1 measurable lesion to be called a target lesion according to RECIST v1.1 • All participants must consent to providing sufficient archival specimen taken during metastatic stage or fresh tumour specimens for tumoural CD8+ T cell testing for enrolment • Presence of tumoural CD8+ T cells based on a predetermined benchmarked PDAC external sample • Normal organ and bone marrow function measured within 28 days prior to first dose of study intervention • Body weight ≥ 35 kg |
• Estado funcional del Eastern Cooperative Oncology Group de 0 1 en la selección/inclusión en el estudio • Gustave Roussy Immune Score de 0 o 1 • Diagnóstico de adenocarcinoma pancreático confirmado histológicamente • Como mínimo 1 lesión medible, a calificar como lesión diana, según RECIST v1.1 • Conformidad en aportar una muestra de archivo suficiente obtenida durante la fase metastásica o muestras frescas del tumor para examen de las células T CD8+ infiltrantes del tumor, para la inclusión en el estudio • Presencia de células T CD8+ infiltrantes del tumor, basada en una muestra externa de adenocarcinoma ductal pancreático como prueba patrón predeterminada • Funciones orgánica y de médula ósea normales, en su determinación en el plazo de los 28 días anteriores a la primera dosis del tratamiento del estudio • Peso corporal >/= 35 kg |
|
E.4 | Principal exclusion criteria |
• Symptomatic central nervous system metastasis or any history of leptomeningeal disease or cord compression • A participant with an already known sensitising mutation or tumour characteristic for pancreatic cancer for which there is a preferred local standard-of-care treatment • History of thromboembolic event within the past 3 months prior to the scheduled first dose of study intervention • Any unresolved toxicities ≥ Grade 2 per Common Terminology Criteria for Adverse Events v5.0 from prior therapy (excluding vitiligo, alopecia, controlled diabetes) • History of solid organ transplantation • History of active primary immunodeficiency • Ongoing or an active infection, including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus. For Coronavirus disease 2019 (COVID-19) infections, a negative polymerase chain reaction test is required • Uncontrolled intercurrent illness • Participants with prior history of myocardial infarction, transient ischemic attack, coronary bypass, or stroke within the past 3 months prior to the first dose of study intervention • Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms calculated from 3 electrocardiograms • Active or prior documented autoimmune or inflammatory disorders • History of another primary malignancy • Receipt of any conventional or investigational anticancer therapy prior to the scheduled first dose of study intervention • Prior receipt of any immune-mediated therapy • Use of immunosuppressive medication within 14 days prior to the first dose of study intervention • Receipt of live, attenuated vaccine within 28 days prior to the first dose of study intervention (Participants can receive non-live COVID-19 vaccines, at the discretion of the Investigator) |
• Metástasis sintomáticas en sistema nervioso central o cualquier antecedente de enfermedad leptomeníngea o de compresión de médula espinal • Conocimiento de mutación sensibilizante o característica tumoral del cáncer pancreático para el que existe un tratamiento de referencia localmente preferido • Antecedente de episodio tromboembólico en los 3 meses anteriores a la primera dosis programada del tratamiento del estudio • Cualquier efecto tóxico no resuelto de Grado >/= 2 según los Common Terminology Criteria for Adverse Events v5.0 del tratamiento previo (a excepción de vitíligo, alopecia y diabetes controlada) • Antecedente de trasplante de órgano sólido • Historia de inmunodeficiencia primaria activa • Infección actual o activa, incluidas tuberculosis, hepatitis B, hepatitis C o virus de la inmunodeficiencia humana. En cuanto a la infección por el coronavirus responsable de la COVID-19, se precisa un resultado negativo de la prueba de la reacción en cadena de la polimerasa • Enfermedad intercurrente no controlada • Antecedente de infarto de miocardio, ataque isquémico transitorio, cirugía de bypass coronario o accidente cerebrovascular en el plazo de los 3 meses anteriores a la primera dosis del tratamiento del estudio • Valor medio (de 3 electrocardiogramas) del intervalo QT corregido según la frecuencia cardíaca utilizando la fórmula de Fridericia (QTcF) >/=470 ms • Trastorno documentado activo o previo de carácter autoinmunitario o inflamatorio • Antecedente de otra neoplasia maligna primaria • Recepción de tratamiento antitumoral, ya sea convencional o experimental, antes de la primera dosis programada del tratamiento del estudio • Recepción previa de cualquier tratamiento de carácter inmunitario • Uso de medicación inmunosupresora en el plazo de los 14 días anteriores a la primera dosis del tratamiento del estudio • Recepción de una vacuna de gérmenes vivos atenuados en el plazo de los 28 días anteriores a la primera dosis del tratamiento del estudio (a criterio del investigador, los participantes puedan recibir vacunas de gérmenes no vivos frente al virus de la COVID-19) |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Safety: - Incidence of AEs, imAEs and SAEs - Clinically meaningful changes from baseline in clinical laboratory parameters, vital signs, and ECG results Efficacy: - OS-12 |
Seguridad: -Incidencia de acontecimientos adversos (adverse events, AEs), acontecimientos adversos de tipo inmune (immune mediated Aes, imAEs) y acontecimientos adversos graves (serious AEs, SAEs) -Cambios clínicamente importantes frente al basal en los resultados de los parámetros de laboratorio, constantes vitales y ECG Eficacia: -Supervivencia global (overall survival) a los 12 meses (OS-12) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
From baseline |
Desde la basal |
|
E.5.2 | Secondary end point(s) |
Efficacy: - According to RECIST v1.1: - (i) ORR, DCR, DoR - (ii) PFS, PFS-4, OS - Serum CA19-9
Immunogenicity : - Incidence of detectable ADAs against AZD0171 and/or durvalumab in serum
Pharmacokinetic : - Summary of PK parameters for AZD0171, total LIF, durvalumab and chemotherapies and/or their metabolites (ie, Cmax, AUC, CL, and terminal elimination t1/2)
Pharmacodynamic : - Assessment of CD8+ T cell tumour infiltration in tumour samples at baseline and on treatment |
Eficacia: -Según RECIST v1.1: -(i) Tasa de respuesta objetiva (objective response rate, ORR), tasa de control de la enfermedad (disease control rate, DCR) y duración de la respuesta (duration of response, DoR) (ii) Mediana de la supervivencia sin progresión (progression free survival, PFS), PFS a los 4 meses (PFS-4) y mediana de la supervivencia global (overall survival, OS) -Niveles séricos de CA19-9
Inmunogenicidad: -Incidencia de anticuerpos antifármaco (anti-drug antibodies, ADAs) detectables frente a AZD0171 y/o durvalumab en suero
Farmacocinética: -Resumen de los parámetros PK de AZD0171, LIF total, durvalumab y chemotherapies y/o sus metabolitos (esto es, Cmax, AUC, CL, y semivida de eliminación terminal [t1/2])
Farmacodinámica: -Evaluación de las células T CD8+ infiltrantes del tumor en muestras de tumor obtenidas en el basal y durante el tratamiento |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
At baseline and on treatment |
en la basal y en tratamiento |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Immunogenicity |
Inmunogenicidad |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 8 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 16 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Canada |
United States |
France |
Spain |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS |
Último paciente, última visita |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 2 |